Table 3.

Hazard ratios for proportional hazards model evaluating effects of variables on TTP

VariablesUnivariate analysis
Multivariate analysis*
Coefficient (SE)Hazard ratio (CI 95%)PCoefficient (SE)Hazard ratio (CI 95%)P
Sarcopenia0.62 (0.3)1.9 (1.0-3.5)0.050.97 (0.4)2.6 (1.2-5.6)0.01
Respiratory tract metastasis−0.13 (0.3)0.9 (0.5-1.4)0.61−0.20 (0.4)0.8 (0.3-1.9)0.57
Liver metastasis0.21 (0.2)1.2 (0.8-1.9)0.340.41 (0.4)1.5 (0.7-3.2)0.30
Other metastasis0.00 (0.3)1.0 (0.6-1.7)0.10−0.29 (0.5)0.8 (0.3-2.1)0.58
Albumin−0.06 (0.0)0.9 (0.9-1.0)0.03−0.09 (0.03)0.9 (0.9-1.0)0.002
Estrogen receptor status§0.66 (0.3)1.9 (1.1-3.6)0.030.75 (0.4)2.1 (1.1-4.2)0.03
HER-2 status−0.08 (0.3)0.9 (0.5-1.6)0.920.58 (0.4)1.8 (0.9-3.6)0.11
Age0.01 (0.0)1.0 (1.0-1.0)0.36
ECOG performance status0.15 (0.3)1.2 (0.6-2.1)0.62
BSA−0.94 (0.7)0.4 (0.1-1.4)0.15
  • NOTE: A univariate and a multivariate Cox regression model were used. Age was not a significant prognostic factor.

  • * n = 52 (3 missing values).

  • Versus nonsarcopenic patients.

  • Versus bone metastasis.

  • § Versus estrogen receptor present.

  • HER-2 status, versus HER-2 receptor not overexpressed.

  • ECOG, versus patients with ECOG performance status 2 to 3.